Department of Internal Diseases No. 1, West Kazakhstan Marat Ospanov State Medical University, 030019, 68 Maresyev Str., Aktobe, Kazakhstan.
Department of Internal Diseases No. 1, West Kazakhstan Marat Ospanov State Medical University, 030019, 68 Maresyev Str., Aktobe, Kazakhstan.
Diabetes Metab Syndr. 2022 Aug;16(8):102569. doi: 10.1016/j.dsx.2022.102569. Epub 2022 Jul 14.
The global obesity epidemic is growing worldwide and its further growth is expected in the future. In obesity, the formation of reactive oxygen species (ROS) and cytokines is normally observed, which damage the genetic material. The purpose of this study was to assess lymphocyte DNA damage before and after metformin use in obese individuals.
The novelty of the article is that for the first time DNA damage in lymphocytes before and after the use of metformin in obese individuals among Kazakh population was studied.
Indirect immunofluorescence analysis using the AKLIDES apparatus was used for the quantitative determination of phosphorylated γ-H2AX (Ser 139) and 53BP1 in order to analyze DNA breaks in the lymphocytes.
The data indicating premature cell aging in the visceral adipose tissue in obese individuals were obtained. An increased hypoxia was observed in combination with an increase in γ-H2AX foci. DNA damage monitoring may become an important part of clinical studies of obesity. Advanced methods to diagnose obesity with early detection of precancerous changes imply a personalized approach, which is ineffective without data from genomic studies.
This study showed that metformin at a dose of 850 mg/day for 3 months for the treatment of obesity (BMI more than 30 kg/m) resulted in a decrease in DNA breaks in the lymphocytes.
全球肥胖症患病率正在不断增加，预计未来还会进一步增长。在肥胖症中，通常会观察到活性氧（ROS）和细胞因子的形成，这些物质会损害遗传物质。本研究旨在评估肥胖个体使用二甲双胍前后淋巴细胞的 DNA 损伤情况。
本文的新颖之处在于，首次研究了哈萨克人群中肥胖个体使用二甲双胍前后淋巴细胞中的 DNA 损伤情况。
使用 AKLIDES 仪器进行间接免疫荧光分析，定量测定磷酸化 γ-H2AX（Ser139）和 53BP1，以分析淋巴细胞中的 DNA 断裂。
获得了表明内脏脂肪组织中细胞过早衰老的相关数据。观察到缺氧增加，同时 γ-H2AX 焦点增加。DNA 损伤监测可能成为肥胖症临床研究的重要组成部分。使用先进方法诊断肥胖症并早期发现癌前病变意味着采用个体化治疗，但如果没有基因组研究的数据支持，这种方法是无效的。
本研究表明，肥胖症患者（BMI 大于 30kg/m²）使用二甲双胍 850mg/天治疗 3 个月可降低淋巴细胞中的 DNA 断裂。
